Analysis Of Prognosis Factors Of Docetaxel In The Treatment Of Metastatic Castration-resistant Prostate Cancer

Objective: The degree of harm in prostate cancer is positively correlated with the progress of the disease.Once entering the stage of metastatic castration-resistant prostate cancer(mCRPC),the patient's condition often deteriorates rapidly in a short period of time.This study was designed to investigate the prognostic factors in patients with mCRPC who are affected by docetaxel in order to guide the clinical and improve the prognosis of patients.Methods: The clinical data of 53 patients with mCRPC in the urinary center of the First Affiliated Hospital of Xinjiang Medical University from June 2013 to June 2018 were retrospectively analyzed.The treatment regimen was docetaxel combined with Androgen-deprivation therapy(ADT).To collect prognostic factors that may affect docetaxel chemotherapy,including the following indicators: ethnicity,age at diagnosis,PSA at diagnosis,Gleason score at diagnosis,duration of ADT,pre-chemotherapy Prostate specific antigen doubling time(PSADT),age at initial chemotherapy,pre-chemotherapy PSA,pre-chemotherapy Eastern Cooperative Oncobgy Group(ECOG)score,pre-chemotherapy hemoglobin(Hgb)concentration,pre-chemotherapy platelet(PLT)count,pre-chemotherapy Ratio of neutrophils to lymphocytes(NLR),pre-chemotherapy Body Mass Index(BMI)index,number of chemotherapy cycles.To explore the prognostic and therapeutic effects of docetaxel chemotherapy in patients with mCRPC.Results: The overall survival rate of patients gradually decreased with time.Univariate analysis showed that the effective duration of ADT,pre-chemotherapy PSADT,ECOG score,Hgb level and number of chemotherapy cycles were related to the survival time of patients.The difference was statistically significant(P<0.05).After multivariate COX regression analysis,the ECOG score before chemotherapy was not statistically significant.Conclusion: The effective duration of ADT,PSADT,Hgb levels before chemotherapy,and the number of chemotherapy cycles are important factors influencing the survival prognosis of patients with mCRPC chemotherapy.The prognosis of patients with PSADT?3.63 months before chemotherapy is relatively good.